Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
about
Nanotechnology-based drug delivery systems for the treatment of Alzheimer's diseaseA practical algorithm for managing Alzheimer's disease: what, when, and why?Cognition enhancers for the treatment of dementia.Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.Donepezil: a clinical review of current and emerging indications.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsEffective countermeasure against poisoning by organophosphorus insecticides and nerve agentsRivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons.Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disordersMicro-scale extraction and analysis of intact carboxylesterase after trapping on an immunoaffinity membrane surface.Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteersDegree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.Clinical relevance of P-glycoprotein in drug therapy.Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer's DiseaseDrug bioactivation, covalent binding to target proteins and toxicity relevance.Neuroinflammation: a potential therapeutic target.A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer's disease treated with rivastigmine transdermal patch.Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease.Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Donepezil: a review.Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.Donepezil: an update.Distinguishing Lewy body dementias from Alzheimer's disease.An update on the pharmacology of galantamine.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended-Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed States.Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.Switching cholinesterase inhibitors in older adults with dementia.Diverse approaches for the enhancement of oral drug bioavailability.Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.
P2860
Q26783306-1A324DED-97A9-4691-8FD4-0677D7FA8637Q26859831-CB9D5483-5C3B-432D-80E0-2729C04DD28EQ30872331-EF301D87-933F-4648-8C2D-E5325D1CABFCQ30998627-7DA5485B-8D93-41D1-8C76-056439EBC413Q33150809-119329A6-B6AD-4045-9F2F-F2F14EC423FAQ33524423-A8A884B4-A081-4F84-AB66-E3F2D14E3BD9Q33586027-3EE24CFA-F947-4BB1-8FF7-878C2DCA00B8Q33652896-B2490577-5C8C-48BC-AFDD-4450DD0C0279Q34327769-486BFBCC-5F64-4B47-A460-B62F78F0F2C7Q34746698-1D1551C3-306D-48F6-9424-C9F88317F1CAQ34965949-B126EE7A-9A91-4FD1-AEC3-48ED37D615F5Q34999015-3C697C09-8B43-4DE8-8413-434B78CAE455Q35045829-A13A9ABA-21D0-492F-8CC4-0B9E350208A7Q35087574-61A6F082-02E8-4817-A183-CC2E0B24F925Q35115042-A5B39B7B-5257-47AA-9B5A-6B45D62CB33FQ35184995-2182914F-8308-4AE2-BC7F-33FD1696DCE0Q35486482-74700200-89CB-4AAB-87EB-959815F12FB1Q35620664-DEE2948C-E7FA-45AA-87E8-5566028C5191Q35725540-A17BDDCB-8C50-4D11-881C-063BAD41987EQ35965628-6967F7BC-B550-4477-8CE2-F79645100F51Q36061821-5FCD4350-709E-4D52-98D4-67C84C133632Q36268282-AE5BD7CD-D349-4434-B19A-7D9F8CE9F9E8Q36372148-9D71EE7A-A8B5-40DF-981D-65B714856E25Q36384458-F917FA49-968D-41E2-BCED-5D51627F9777Q36475090-525C993B-3100-4EDA-B0F2-9E0ADA8E5E5FQ36544994-EF13EB9C-63B8-4BFC-BE78-5427C8081C5CQ36678091-26CE13EC-EB53-4E2D-BB51-C228CC7AE301Q36808057-2DA66D7E-211F-4397-8CF3-D020023F313EQ36998833-87494573-0485-40D0-8394-E2BE9F7E6DDCQ37016107-17A003CE-44DC-49B2-B4BB-82512A1AB0BBQ37079954-DE3E6FC5-3F30-450F-B334-8B3851A2C082Q37218956-83ECE6FF-EE9B-4ED3-9759-78BF18D84585Q37282357-F50632F9-42A8-4567-801E-EE7612520181Q37337050-F4F2915B-CCC3-419A-B5CB-64E544F894CBQ37385577-718E3CA3-6B0D-41C0-AAD8-AA474885580FQ37658872-D0675CBD-65DB-4F42-85BD-1852770740DFQ37806328-A8BA1905-E58B-4419-9F8C-9C093C4F3EACQ37863645-46959703-B768-49AC-A4D7-992747850595Q37910243-E50B9F65-23FF-4BBE-B04F-E0D6427E50A9Q38217301-831BCAD2-DB8F-47AE-B217-E9A8D9F1CA5C
P2860
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@ast
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@en
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@nl
type
label
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@ast
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@en
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@nl
prefLabel
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@ast
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@en
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@nl
P2093
P1476
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
@en
P2093
Gary W Small
Kara L Shirley
Michael W Jann
P304
P356
10.2165/00003088-200241100-00003
P577
2002-01-01T00:00:00Z
P6179
1044261370